Fluctuations of cN-II expression and activity have been associated with highly proliferating cells and neurological disorders [12, 13], and mutations in NT5C2 (the gene encoding cN-II) have been reported to drive pharmacological resistance in hematological tumors [14, 15]. This evidence concerns the gene NT5C2 and nervous system disorder.